DPP4 and atrial fibrillation: Among diabetic patients on metformin, dipeptidyl peptidase-4 inhibitor was associated with a lower risk of new-onset AF as compared with other oral hypoglycemic agents suggesting anti-inflammatory effect of dipeptidyl peptidase-4 inhibitor can have additional benefit besides from glycemic control [33, 34].